Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.81B | $2.84B | $1.90B | $2.01B | $2.09B | $2.31B | $2.61B | $2.93B | $3.15B | $3.31B |
| Revenue growth | — | 0.9% | -32.8% | 5.4% | 4.1% | 10.7% | 12.8% | 12.2% | 7.7% | 5.0% |
| Operating income | $609M | $604M | $594M | $586M | — | — | — | — | — | — |
| Operating margin | 21.7% | 21.3% | 31.2% | 29.2% | — | — | — | — | — | — |
| Net income | $6.14M | $200M | -$176M | $109M | -$672M | $191M | $273M | -$21.7M | $256M | -$1.10B |
| Net margin | 0.2% | 7.0% | -9.2% | 5.4% | -32.2% | 8.2% | 10.5% | -0.7% | 8.1% | -33.3% |
| EPS (diluted) | $0.07 | $2.30 | -$2.01 | $1.24 | -$7.59 | $2.10 | $2.98 | -$0.24 | $2.78 | -$12.16 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $361M | $400M | $414M | $333M | $659M | $374M | $381M | $462M | $130M | $132M |
| Capital expenditures | $307M | $274M | $253M | $233M | $225M | $245M | $296M | $424M | $690M | $572M |
| Free cash flow | $54.0M | $125M | $161M | $100M | $434M | $130M | $84.4M | $38.2M | -$561M | -$440M |
| Share buybacks | — | — | — | — | — | — | — | — | — | $50.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $57.1M | $67.3M | $50.5M | $99.5M | $379M | $134M | $97.6M | $100M | $76.3M | $133M |
| Total assets | $6.02B | $6.42B | $6.17B | $6.88B | $6.50B | $4.77B | $4.99B | $5.36B | $5.96B | $5.53B |
| Total liabilities | $3.84B | $3.83B | $3.81B | $4.34B | $4.54B | $2.19B | $2.09B | $2.47B | $2.77B | $3.39B |
| Long-term debt | $3.25B | $3.21B | $3.16B | $3.11B | $2.97B | $1.48B | $1.36B | $1.34B | $1.88B | $2.47B |
| Shareholders' equity | $2.17B | $2.57B | $2.33B | $2.51B | $1.90B | $2.52B | $2.81B | $2.78B | $3.07B | $1.95B |
| Retained earnings | $220M | $429M | $253M | $362M | -$310M | -$120M | $153M | $132M | $387M | -$766M |
| Shares (wtd avg diluted) | 86.0M | 87.1M | 87.4M | 87.8M | 88.6M | 90.8M | 91.6M | 90.9M | 92.1M | 90.7M |
Every figure is extracted from Acadia Healthcare Company, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.